Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14231805 | 0.76 | DYRK1A (0.39) | DYRK1APIK3C3DYRK1BMAPTRAB9A | |
| SCHEMBL11637557 | 0.75 | MAPT (0.51) | DYRK1ADYRK1BMEN1KMT2AMAPT | |
| SCHEMBL4098480 | 0.73 | DYRK1A (0.42) | DYRK1ADYRK1BMEN1KMT2AMAPT | |
| SCHEMBL31326188 | 0.73 | CA1 (0.41) | CA1CA2MEN1KMT2AMAPT | |
| SCHEMBL854857 | 0.73 | KMT2A (0.47) | CA1CA2DYRK1AMEN1KMT2A | |
| SCHEMBL1433126 | 0.73 | DYRK1A (0.42) | CA1CA2DYRK1APIK3C3DYRK1B | |
| SCHEMBL760353 | 0.73 | NPC1 (0.48) | DYRK1ADYRK1BMEN1KMT2AMAPT | |
| SCHEMBL1516710 | 0.72 | DYRK1A (0.43) | CA1CA2DYRK1ADYRK1BMEN1 | |
| SCHEMBL856143 | 0.72 | CA1 (0.40) | CA1CA2MEN1KMT2AMAPT | |
| SCHEMBL11982873 | 0.72 | DYRK1A (0.41) | DYRK1ADYRK1BMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507231-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011067366-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067366-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | PI4KA, PIP4K2B, PI4KB | CA1 4085/4885CA2 1529/4885DYRK1A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.